Saturday, 31 October 2026European Markets

BURELLE And AKWEL Have A High Dividend Yield And Return On Equity In The Auto Parts Industry.

Loading stream...

(vianews) - burelle (bur.pa) is among this list of stock assets with the highest dividend rate and return on equity on the auto parts industry.

financial asset price forward dividend yield return on equity
burelle (bur.pa) €497.00 2.96% 4.63%
akwel (akw.pa) €13.50 2.75% 2.61%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. burelle (bur.pa)

2.96% forward dividend yield and 4.63% return on equity

burelle sa, through its subsidiaries, offers automotive equipment, intelligent body systems, and clean energy systems and modules in france and internationally. the company offers plastic and composite body parts and systems, and fuel and pollution control systems; researches and develops lightweight vehicles, pollution control systems, and support for new engines; and develops, assembles, and provides logistics for automotive front-end modules. it also operates a venture capital company that invests in various companies through a network of family offices, investment funds, and financial institutions; and owns an office building in levallois, as well as various real estate assets in the lyon region. burelle sa was founded in 1957 and is headquartered in lyon, france.

earnings per share

as for profitability, burelle has a trailing twelve months eps of €-66.1.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 4.63%.

yearly top and bottom value

burelle's stock is valued at €497.00 at 11:40 est, way under its 52-week high of €612.00 and way above its 52-week low of €419.00.

moving average

burelle's worth is under its 50-day moving average of €510.26 and higher than its 200-day moving average of €480.85.

volume

today's last reported volume for burelle is 1 which is 98.93% below its average volume of 94.

more news about burelle.

2. akwel (akw.pa)

2.75% forward dividend yield and 2.61% return on equity

akwel sa manufacture of automotive and heavy goods vehicle components in france and internationally. it offers fluid management, mechanisms, and structural parts for electric vehicles. the company's products include body pipes, flow regulation valves, anti-return valves, pulsation dampeners or temperature, and pressure sensors; air distributors, turbo air intake and output pipes and exchangers, exhaust gas recirculation pipes, and cylinder head covers. it also offers electronic management of hardware, software, transfer, storage, reheating, and pumping systems. the company was formerly known as mgi coutier sa and changed its name to akwel in june 2018. the company was founded in 1972 and is headquartered in champfromier, france. akwel sa is a subsidiary of coutier developpement.

earnings per share

as for profitability, akwel has a trailing twelve months eps of €3.2.

pe ratio

akwel has a trailing twelve months price to earnings ratio of 4.22. meaning, the purchaser of the share is investing €4.22 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 2.61%.

volume

today's last reported volume for akwel is 1002 which is 90.35% below its average volume of 10387.

more news about akwel.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com